Live Updates: COVID-19 Cases
  • World 30,982,249
    World
    Confirmed: 30,982,249
    Active: 7,438,296
    Recovered: 22,582,580
    Death: 961,373
  • USA 6,967,403
    USA
    Confirmed: 6,967,403
    Active: 2,539,886
    Recovered: 4,223,693
    Death: 203,824
  • India 5,398,230
    India
    Confirmed: 5,398,230
    Active: 1,011,732
    Recovered: 4,299,724
    Death: 86,774
  • Brazil 4,528,347
    Brazil
    Confirmed: 4,528,347
    Active: 571,687
    Recovered: 3,820,095
    Death: 136,565
  • Russia 1,097,251
    Russia
    Confirmed: 1,097,251
    Active: 171,450
    Recovered: 906,462
    Death: 19,339
  • Peru 762,865
    Peru
    Confirmed: 762,865
    Active: 123,659
    Recovered: 607,837
    Death: 31,369
  • Mexico 694,121
    Mexico
    Confirmed: 694,121
    Active: 124,639
    Recovered: 496,224
    Death: 73,258
  • South Africa 659,656
    South Africa
    Confirmed: 659,656
    Active: 54,282
    Recovered: 589,434
    Death: 15,940
  • Spain 659,334
    Spain
    Confirmed: 659,334
    Active: 628,839
    Recovered: ?
    Death: 30,495
  • Chile 444,674
    Chile
    Confirmed: 444,674
    Active: 14,319
    Recovered: 418,101
    Death: 12,254
  • France 442,194
    France
    Confirmed: 442,194
    Active: 319,346
    Recovered: 91,574
    Death: 31,274
  • Iran 419,043
    Iran
    Confirmed: 419,043
    Active: 37,293
    Recovered: 357,632
    Death: 24,118
  • UK 390,358
    UK
    Confirmed: 390,358
    Active: 348,599
    Recovered: ?
    Death: 41,759
  • Bangladesh 347,372
    Bangladesh
    Confirmed: 347,372
    Active: 88,073
    Recovered: 254,386
    Death: 4,913
  • Saudi Arabia 329,271
    Saudi Arabia
    Confirmed: 329,271
    Active: 15,383
    Recovered: 309,430
    Death: 4,458
  • Pakistan 305,031
    Pakistan
    Confirmed: 305,031
    Active: 6,572
    Recovered: 292,044
    Death: 6,415
  • Turkey 301,348
    Turkey
    Confirmed: 301,348
    Active: 27,786
    Recovered: 266,117
    Death: 7,445
  • Italy 296,569
    Italy
    Confirmed: 296,569
    Active: 43,161
    Recovered: 217,716
    Death: 35,692
  • Germany 272,308
    Germany
    Confirmed: 272,308
    Active: 19,342
    Recovered: 243,500
    Death: 9,466
  • Canada 142,774
    Canada
    Confirmed: 142,774
    Active: 9,376
    Recovered: 124,187
    Death: 9,211
  • Netherlands 91,934
    Netherlands
    Confirmed: 91,934
    Active: 85,659
    Recovered: ?
    Death: 6,275
  • China 85,279
    China
    Confirmed: 85,279
    Active: 168
    Recovered: 80,477
    Death: 4,634
  • Australia 26,897
    Australia
    Confirmed: 26,897
    Active: 2,081
    Recovered: 23,967
    Death: 849
  • S. Korea 22,975
    S. Korea
    Confirmed: 22,975
    Active: 2,434
    Recovered: 20,158
    Death: 383
  • New Zealand 1,811
    New Zealand
    Confirmed: 1,811
    Active: 67
    Recovered: 1,719
    Death: 25

Low-cost drug lowers death by third among ventilated COVID-19 patients, scientists say

Author at TechGenyz Health
Low Cost Drug
Credit: Unsplash

Low doses of the steroid dexamethasone can reduce deaths by one-third in ventilated COVID-19 patients, according to researchers who assessed the performance of the inexpensive drug in more than 2,100 patients.

The analysis is part of the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial which was established to test a range of potential therapies for COVID-19, including low-dose dexamethasone — a steroid treatment.

The RECOVERY trial included over 11,500 patients, enrolled from more than 175 hospitals in the UK, noted a statement by the University of Oxford.

In the trial, a total of 2,104 patients were randomized to receive dexamethasone 6 milligrams once per day — either by mouth or by intravenous injection — for ten days and were compared with 4321 patients randomized to usual care alone.

Among the patients who received usual care alone, mortality was highest in those who required ventilation (41 percent), intermediate in those patients who required oxygen only (25 percent), and lowest among those who did not require any respiratory intervention (13%), the scientists said.

They found that dexamethasone reduced deaths by one-third in ventilated patients, and by one fifth in other patients receiving oxygen only.

However, the researchers said there was no benefit from dexamethasone among the patients who did not require respiratory support.

Based on these results, the scientists believe that the drug could prevent nearly one death in the treatment of around eight ventilated patients, or around 25 patients requiring oxygen alone.

“Dexamethasone is the first drug to be shown to improve survival in COVID-19. This is an extremely welcome result,” said Peter Horby, one of the chief investigators of the trial from the University of Oxford in the UK.

The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become the standard of care in these patients. – Horby said.

The drug, according to the scientists, is inexpensive, on the shelf, and can be used immediately to save lives worldwide.

These preliminary results from the RECOVERY trial are very clear –dexamethasone reduces the risk of death among patients with severe respiratory complications, – Martin Landray, another chief investigator of the trial from the University of Oxford.

“COVID-19 is a global disease it is fantastic that the first treatment demonstrated to reduce mortality is one that is instantly available and affordable worldwide,” Landray added.

Career

Subscribe